Molecular biological investigation of temozolomide and KC7F2 combination in U87MG glioma cell line

Basit Öğe Kaydı
dc.authorwosidBiray Avcı, Cigir/GWV-1665-2022
dc.contributor.authorAbbaszade, Zaka
dc.contributor.authorBagca, Bakiye Goker
dc.contributor.authorAvci, Cigir Biray
dc.date.accessioned2023-01-12T19:54:54Z
dc.date.available2023-01-12T19:54:54Z
dc.date.issued2021
dc.departmentN/A/Departmenten_US
dc.description.abstractGlioblastom Multiforme (GBM) is the most invasive and malignant member of the IV grade of the subclass Astrocytoma according to the last assessment of the 2016 WHO report. Due to the resistance to treatment and weak response, as well as the topographical structure of the blood brain barrier, the treatment is also difficult due to the severe clinical manifestation, and new treatment methods and new therapeutic agents are needed. Temozolomide (TMZ) is widely used in the treatment of glioblastoma and is considered as the primary treatment modality. TMZ, a member of the class of cognitive agents, is currently considered the most effective drug because it can easily pass through the blood brain barrier. Glucose metabolism is a complex energy producing machine that, a glucose molecule produces 38 molecules of ATP after full glycolytic catabolism. According to Otto Warburg's numerous studies cancer cells perform the first glycolytic step without entering the mitochondrial step. These cells produce lactic acid and make the micro-media more acidic even in aerobic conditions. This phenomenon is attributed to the Warburg hypothesis and either as aerobic glycolysis. Although glycolysis enzymes are the primary actors of this phenotypic expression, some genetic and epigenetic factors are no exception. We experimentally used KC7F2 active ingredient to target cancer metabolism. In our study, we evaluated cancer metabolism in combination with the effect of TMZ chemotherapeutic agent, examining the effect of two different agents separately and in combination to observe the effects of cancer cell proliferation, survival, apoptosis and expression of metabolism genes on expression. We observed that the combined effect of reduced the effective dose of the TMZ alkylating agent and that the effect was increased and the effect of the combined teraphy is assessed from a metabolic point of view and that it suppresses aerobic glycolysis.en_US
dc.identifier.doi10.1016/j.gene.2021.145445
dc.identifier.issn0378-1119
dc.identifier.issn1879-0038
dc.identifier.pmid33484758en_US
dc.identifier.urihttps://doi.org/10.1016/j.gene.2021.145445
dc.identifier.urihttps://hdl.handle.net/11454/76565
dc.identifier.volume776en_US
dc.identifier.wosWOS:000620294400007en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofGeneen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGlycolysisen_US
dc.subjectWarburg hypothesisen_US
dc.subjectTemozolomideen_US
dc.subjectKC7F2en_US
dc.subjectU87 MGen_US
dc.subjectGlioblastomaen_US
dc.titleMolecular biological investigation of temozolomide and KC7F2 combination in U87MG glioma cell lineen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu